CACNB3 and glioblastoma: Also, within the Project Achilles CRISPR/Cas9 dataset, the drug target CACNB3 had the lowest average gene effect score across the drug targets for nimodipine (−0.4559023), indicating that CACNB3 is potentially essential in these GBM cell lines (Fig. 6F).